T1695

Phase 2Small molecule

LLaboratoires Thea

T1695 is one of 6 small molecule programs targeting Keratoconjunctivitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

KeratoconjunctivitisNot yet recruiting

KeratoconjunctivitisPhase 2

Not yet recruiting

Competition

Competitive Landscape

6 competitors in Keratoconjunctivitis

#DrugCompanyPhaseTrials

Neoral

Novartis

Approved

—2

Prograf

VVeloxis Pharmaceuticals

Approved

2 3

Lotemax

PPharmos

Approved

2 4

Decadron

AAspen Global Incorporated

Approved

1 5

Betadine

BBecton, Dickinson and Company

Preclinical

1 6

T1695

LLaboratoires Thea

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Not yet recruiting

Keratoconjunctivitis

NCT07169695

Clinical

Trials by Indication[1]

Keratoconjunctivitis1 trial

A Study to Compare the Effectiveness and Safety of T1695 Versus Ciclosporin in Participants With Moderate to Severe Vernal Keratoconjunctivitis

Not yet recruiting·LLaboratoires Thea·Phase 2·NCT07169695·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for T1695. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — T1695 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for T1695. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Laboratoires Thea company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: LLaboratoires Thea

T1695

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Keratoconjunctivitis1 trial

References

Drug Info

Quick Facts

Related News